Inhibition of P450 17 as a New Strategy for the Treatment of Prostate Cancer

Author(s): F. Leroux.

Journal Name: Current Medicinal Chemistry

Volume 12 , Issue 14 , 2005

Become EABM
Become Reviewer

Abstract:

The cytochrome P450 monooxygenase enzyme system is involved in the synthesis and/or degradation of a large number of endogenous compounds and in the biotransformation of drugs and other xenobiotics. 17α-Hydroxylase-C17,20-lyase (P450 17, CYP 17) is the key enzyme of the androgen biosynthesis. As androgens have been implicated in the development and progression of prostate cancer, this enzyme has become a promising therapeutic target. This paper will review the possible approaches dealing with P450 17 inhibition as a chemotherapeutic strategy in the struggle against prostate cancer.

Keywords: androgen, hydroxylase-c, lyase, cyp, prostate cancer, steroidal inhibitors, non-steroidal inhibitors, abiraterone, liarozole

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 14
Year: 2005
Page: [1623 - 1629]
Pages: 7
DOI: 10.2174/0929867054367185
Price: $58

Article Metrics

PDF: 8